A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Abatacept (Primary) ; Mycophenolate mofetil; Prednisone
  • Indications Lupus nephritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ALLURE
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 16 Jun 2018 Primary endpoint of proportion of subjects achieving Complete Response of renal disease has not been met, according to results presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
    • 13 Jun 2018 According to a Bristol-Myers Squibb media release, data from this trial will be presented at the Annual European Congress of Rheumatology (EULAR 2018).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top